Fuzuloparib: Difference between revisions
CSV import |
CSV import |
||
| Line 3: | Line 3: | ||
| verifiedfields = changed | | verifiedfields = changed | ||
| verifiedrevid = 477002547 | | verifiedrevid = 477002547 | ||
| image = Fuzuloparib.svg | | image = [[File:Fuzuloparib.svg|Chemical structure of Fuzuloparib|thumb|right]] | ||
| | | tradename = | ||
| | | synonyms = | ||
| | | IUPAC_name = | ||
| | | CAS_number = | ||
| ATC_prefix = | |||
| ATC_suffix = | |||
| PubChem = | |||
| DrugBank = | |||
| ChemSpiderID = | |||
| UNII = | |||
| KEGG = | |||
| ChEMBL = | |||
| C= | |||
| H= | |||
| N= | |||
| O= | |||
| molecular_weight = | |||
}} | }} | ||
'''Fuzuloparib''' is a [[PARP inhibitor | '''Fuzuloparib''' is a [[poly (ADP-ribose) polymerase]] (PARP) inhibitor that is used in the treatment of certain types of [[cancer]]. It is part of a class of drugs that target the DNA damage response pathway, which is crucial for the repair of single-strand breaks in DNA. | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Fuzuloparib | Fuzuloparib works by inhibiting the activity of the PARP enzyme. PARP enzymes are involved in the repair of single-strand DNA breaks through the base excision repair pathway. Inhibition of PARP leads to the accumulation of DNA damage, ultimately resulting in cell death, particularly in cancer cells that are already deficient in other DNA repair mechanisms, such as those with [[BRCA1]] or [[BRCA2]] mutations. | ||
==Clinical Use== | ==Clinical Use== | ||
Fuzuloparib is primarily | Fuzuloparib is primarily used in the treatment of [[ovarian cancer]], [[breast cancer]], and other cancers that have shown sensitivity to PARP inhibition. It is particularly effective in patients with [[BRCA]] mutations, as these mutations impair the homologous recombination repair pathway, making cancer cells more reliant on PARP-mediated repair. | ||
==Administration== | ==Administration and Dosage== | ||
Fuzuloparib is administered orally | Fuzuloparib is administered orally. The dosage and treatment regimen depend on the specific type of cancer being treated, the stage of the disease, and the patient's overall health and response to the drug. | ||
==Side Effects== | ==Side Effects== | ||
Common side effects of Fuzuloparib include | Common side effects of Fuzuloparib include nausea, fatigue, anemia, and thrombocytopenia. Patients may also experience more severe side effects such as myelodysplastic syndrome or acute myeloid leukemia, although these are less common. | ||
==Research and Development== | ==Research and Development== | ||
Fuzuloparib is the | Fuzuloparib is the subject of ongoing research to determine its efficacy in combination with other cancer therapies, such as [[chemotherapy]] and [[immunotherapy]]. Clinical trials are also exploring its use in other types of cancer beyond those with known BRCA mutations. | ||
==Related Pages== | ==Related Pages== | ||
* [[PARP inhibitor]] | |||
* [[BRCA1]] | |||
* [[BRCA2]] | |||
* [[Ovarian cancer]] | * [[Ovarian cancer]] | ||
* [[Breast cancer]] | * [[Breast cancer]] | ||
[[Category:Antineoplastic drugs]] | [[Category:Antineoplastic drugs]] | ||
[[Category:PARP inhibitors]] | [[Category:PARP inhibitors]] | ||
Latest revision as of 01:45, 6 March 2025
A PARP inhibitor used in cancer treatment
| Fuzuloparib | |
|---|---|
[[File: | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Fuzuloparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that is used in the treatment of certain types of cancer. It is part of a class of drugs that target the DNA damage response pathway, which is crucial for the repair of single-strand breaks in DNA.
Mechanism of Action[edit]
Fuzuloparib works by inhibiting the activity of the PARP enzyme. PARP enzymes are involved in the repair of single-strand DNA breaks through the base excision repair pathway. Inhibition of PARP leads to the accumulation of DNA damage, ultimately resulting in cell death, particularly in cancer cells that are already deficient in other DNA repair mechanisms, such as those with BRCA1 or BRCA2 mutations.
Clinical Use[edit]
Fuzuloparib is primarily used in the treatment of ovarian cancer, breast cancer, and other cancers that have shown sensitivity to PARP inhibition. It is particularly effective in patients with BRCA mutations, as these mutations impair the homologous recombination repair pathway, making cancer cells more reliant on PARP-mediated repair.
Administration and Dosage[edit]
Fuzuloparib is administered orally. The dosage and treatment regimen depend on the specific type of cancer being treated, the stage of the disease, and the patient's overall health and response to the drug.
Side Effects[edit]
Common side effects of Fuzuloparib include nausea, fatigue, anemia, and thrombocytopenia. Patients may also experience more severe side effects such as myelodysplastic syndrome or acute myeloid leukemia, although these are less common.
Research and Development[edit]
Fuzuloparib is the subject of ongoing research to determine its efficacy in combination with other cancer therapies, such as chemotherapy and immunotherapy. Clinical trials are also exploring its use in other types of cancer beyond those with known BRCA mutations.
